New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
Johnson & Johnson (JNJ) presented two-year Phase 3 data for ICOTYDE® (icotrokinra) at Fall Clinical Dermatology 2026. The study showed high, sustained response rates in adults and adolescents with plaque psoriasis, with 72% achieving clear or almost clear skin and a favorable safety profile. ICOTYDE is the first targeted oral peptide blocking the IL-23 receptor. The company highlights its potential as a first-line systemic therapy.
How this was made
The 30-second read
Why it matters
The two-year data reinforce the drug's efficacy and safety, likely supporting commercial rollout and revenue forecasts.
Market read
First report of pivotal Phase 3 data for a major pharma pipeline asset; may influence JNJ valuation.
What to watch
Potential competition from existing biologics and the need for regulatory approval timelines.
Background
Johnson & Johnson's ICOTYDE is the first oral peptide targeting IL-23 for plaque psoriasis, recently approved in multiple regions.
Ticker impact
Johnson & Johnson announced first two-year Phase 3 data for ICOTYDE, showing ~72% PASI 90 response and sustained safety.
likely upward pressure as investors price in a new blockbuster psoriasis therapy.
Phase 3 results are material for a large pharma pipeline; JNJ's share price typically reacts to breakthrough data.
Market effects
Strengthens the dermatology/psoriasis treatment segment and may pressure competitors.
U.S. and European markets may see modest gains in pharma stocks.
Adds a new oral IL-23 blocker to the global psoriasis therapy landscape.
Counterpoint
If pricing or reimbursement challenges arise, the data may not translate into sales.
Key entities
- CompanyJohnson & Johnson
US pharmaceutical giant developing ICOTYDE.
- ProductICOTYDE (icotrokinra)
Oral peptide therapy for moderate-to-severe plaque psoriasis.
